CLINICAL ROLE -
Topical Treatments Carry Risk in Atopic Dermatitis
Some atopic dermatitis patients at risk for developing contact dermatitis from certain common ingredients in topical products.
Read More
Discontinuing Omalizumab Can Exacerbate Asthma
Patients who discontinued long-term treatment with omalizumab more likely to experience severe asthma exacerbation.
Ustekinumab Shows Promise in Severe Atopic Dermatitis
Ustekinumab is a monoclonal antibody approved by the FDA to treat plaque psoriasis, psoriatic arthritis, and active Crohn's disease.